Favorable safety and tolerability, consistent with the established safety profile of levacetylleucine Regulatory submissions planned in the US, Europe, and other jurisdictions for levacetylleucine in ...
Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...
A friend and colleague told me about an amazing event, the Illumination Biopharma Leadership Ball, which will be held on Saturday, May 11, at the Museum of Fine Arts in Boston. The event benefits ...
Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...
Ataxia telangiectasia (A‐T) is a rare autosomal recessive disorder that manifests with progressive neurodegeneration, immunodeficiency, oncogenic predisposition and heightened radiosensitivity.
Quince’s transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Having a rare genetic disease is actually pretty common. Rare diseases affect approximately 1 in 10 individuals, and more than 30 million people in the U.S. have a rare disease diagnosis. What makes ...
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting Quince Therapeutics, Inc. (Nasdaq: QNCX), ...
Having a rare genetic disease is actually pretty common. Rare diseases affect approximately 1 in 10 individuals, and more than 30 million people in the U.S. have a rare disease diagnosis. What makes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results